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Human epidermal growth factor receptor 2 (HER2 or ErbB2) can be overexpressed,
amplified and/or mutated in malignant tumors, and is a candidate for therapeutic target-
ing. However, molecular associations and clinical significances of these alterations were
controversial in lung cancer. In this study, we investigated the frequency and clinicopatho-
logical significance of HER2 dysregulation in patients with lung adenocarcinoma. HER2
protein overexpression, gene amplification, and gene mutation were evaluated by immu-
nohistochemistry (IHC), silver in situ hybridization, and direct sequencing, respectively.
The H-scoring method and American Society of Clinical Oncology/College of American
Pathologists breast cancer guidelines were used to interpret IHC results. Genetic analy-
ses of EGFR and KRAS mutations, and of ALK and ROS1 rearrangements, were also
performed. Of the 321 adenocarcinoma patients identified, HER2 overexpression (H-
score 200) and gene amplification were found in 6 (1.9%) and 46 (14.3%), respectively.
HER2 overexpression was correlated with papillary predominant histology; furthermore, it
indicated poor overall survival and was an independent prognostic factor. HER2 amplifi-
cation was associated with pleural invasion and showed a tendency towards shorter over-
all and disease-free survival. High-level gene amplification (HER2/CEP17 ratio 5 or
copy number 10) was a poor prognostic factor for disease-free survival. HER2 muta-
tions were detected in 6.7% (7 of 104) of driver oncogene-negative adenocarcinomas.
Our study suggests that HER2 overexpression or amplification is a poor prognostic factor
in lung adenocarcinoma, although the frequency of such events is low. Since molecular
targeted agents are being tested in clinical trials, awareness of the specific HER2 status
can influence the prognostic stratification and treatment of patients with molecularly
defined subsets of lung adenocarcinoma.
Background
Lung cancer is estimated to be responsible for more than one-quarter (27%) of all cancer-
related deaths worldwide [1]. Molecular-based research and systematic genomic studies of this
disease have revealed several driver mutations such as those of the epidermal growth factor
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receptor (EGFR) as well as rearrangements of the anaplastic lymphoma kinase (ALK) gene;
tyrosine kinase inhibitors (TKIs) have been developed against the proteins encoded by these
genes. More recently, comprehensive molecular profiling of lung adenocarcinoma from The
Cancer Genome Atlas data has identified additional driver gene alterations, including amplifi-
cations in human epidermal growth factor receptor 2 (HER2 or ERBB2) [2].
HER2 is a receptor tyrosine kinase and a member of the human EGFR (ErbB) family. It is
encoded by the HER2 gene located on the long arm of chromosome 17 (17q21), and activates
downstream signaling pathways such as those involving PI3K-Akt and MEK/ERK to elicit cell
proliferation and migration [3]. Many breast and gastric cancers have been found to carry
HER2 amplifications, and the protein is overexpressed in these tumors. Monoclonal antibodies
directed against HER2, such as trastuzumab (Herceptin), has improved patient outcomes
[4,5].
HER2 genetic alterations have also been described in non-small cell lung cancer (NSCLC).
Gene amplification is found in 10–20% of these cancers, while HER2 protein overexpression
has been observed in 2.4–38% [6–11]. Moreover, HER2mutations, such as in-frame insertions,
have been detected in 2–4% of lung adenocarcinomas [2,12,13]. However, the molecular asso-
ciations of HER2 gene amplification, mutation, and HER2 protein overexpression in lung
cancers were controversial [10,14,15]. Although clinical trials of HER2-targeting agents have
produced disappointing results, certain subgroups of patients with high HER2 expression,
gene amplification, or mutations have shown good responses to HER2-targeted therapy [16–
20]. Additional novel drugs are also under ongoing investigation.
In this study, we aimed to investigate clinicopathological characteristics and implications of
HER2 protein overexpression and gene amplification in NSCLC. Additionally, we performed
mutational analysis of HER2 in a subset of adenocarcinoma, and examined correlations with
other genetic alterations.
Materials and methods
Patients and clinical samples
Archived formalin-fixed, paraffin-embedded (FFPE) primary tumor tissues were obtained
from consecutive NSCLC patients who underwent surgical resection at our institution
between 2005 and 2011. Patients who had undergone preoperative treatment or had another
malignancy within the 5 years prior to NSCLC diagnosis, or else had inadequate tissue samples
or insufficient clinical data, were excluded. Clinical data were collected and reviewed from the
patient records. Histologic features were evaluated by two pathologists (H.S.S and E.K.K.) and
classified according to the Seventh American Joint Committee on Cancer TNM cancer classifi-
cation system [21] and the World Health Organization 2015 criteria [22]. The median follow-
up period was 62 months (range: 1–126 months) after surgical resection. This retrospective
study was approved by the Institutional Review Board of Severance Hospital (No. 4-2015-
0561).
Tissue microarray preparation
Sections of FFPE tissues were prepared and stained with hematoxylin and eosin. Areas repre-
sentative of the tumor were selected and sampled to construct tissue microarrays (TMAs)
under a microscope. Two different cores per case (2–3 mm in diameter) were punched out
from donor blocks and placed into 6×5 or 8×6 recipient blocks. The core areas of all TMA
blocks were confirmed to contain at least 25% tumor tissue.
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Immunohistochemistry and scoring criteria
Protein expression was evaluated using the PATHWAY anti-HER2/neu (4B5) rabbit monoclo-
nal primary antibody (Ventana Medical Systems, Tucson, AZ, USA). Immunohistochemistry
(IHC) was performed on 4-μm TMA tissue sections by using the Ventana Bench Mark XT
Autostainer (Ventana Medical Systems, Tucson, AZ, USA). HER2 IHC was assessed using two
different methods: the H-scoring system [23] and American Society of Clinical Oncology/Col-
lege of American Pathologists (ASCO/CAP) guidelines of breast cancer [24]. Semiquantitative
H-scoring assessment is performed by multiplying staining intensity (0, none; 1, weak or
barely detectable; 2, moderate; and 3, strong) with the percentage of positive cells (0–100%).
H-scoring took into account both membranous and cytoplasmic staining. The final scores ran-
ged from 0 to 300 and were classified as high (200H-score 300), intermediate (100H-
score < 200), low (0 < H-score < 100), and negative (H-score = 0). As for the ASCO/CAP
breast cancer guidelines, the final score ranged between 0 and 3 based on membranous stain-
ing (0: no staining or incomplete membrane staining that is faint/barely perceptible and com-
prises10% of the invasive tumor cells; 1+: incomplete membrane staining that is faint/barely
perceptible and comprises >10% of the invasive tumor cells; 2+: circumferential membrane
staining that is incomplete and/or weak/moderate and encompasses >10% of the invasive
tumor cells, or complete and circumferential membrane staining that is intense but comprises
10% of the invasive tumor cells; and 3+: circumferential membrane staining that is complete
and intense). Scores of 0 and 1 were considered negative; scores of 2 and 3 were considered
equivocal and positive, respectively.
Silver in situ hybridization and interpretation
Silver in situ hybridization (SISH) was performed using the INFORM HER2 Dual ISH DNA
Probe Cocktail assay (Ventana Medical Systems) with an automated slide stainer according to
the manufacturer’s protocols (BenchMark XT; Ventana Medical Systems). Black (HER2) and
red (CEP17) signals were quantified in 60 non-overlapping tumor cells. According to the
ASCO/CAP guidelines for dual-probe ISH [24], interpretation of HER2 gene amplification
was defined as follows: negative, HER2/CEP17 ratio <2.0 with an average HER2 copy number
<4.0 signals/cell; equivocal, HER2/CEP17 ratio <2.0 with an average HER2 copy number4.0
but<6.0 signals/cell; positive, HER2/CEP17 ratio2.0 with an average HER2 copy number
4.0 signals per cell or a HER2/CEP17 ratio2.0 with an average HER2 copy number <4.0
signals/cell or a HER2/CEP17 ratio <2.0 with an average HER2 copy number6.0 signals/cell.
Additionally, tumors harboring an average copy number of10.0 signals/cell or a HER2/
CEP17 ratio5.0 were considered to have high-level amplification.
HER2, EGFR, and KRAS mutation analysis
To determine the HER2, EGFR, and KRASmutation status, DNA was extracted using the
DNeasy isolation kit (Qiagen, Valencia, CA, USA) from FFPE tissues according to the manu-
facturer’s instructions. For the HER2 gene, direct DNA sequencing of exons 18 through 21 was
performed in a subset of our cohort (n = 60, comprising cases with driver mutation-negative
adenocarcinomas). For EGFR gene analysis, direct DNA sequencing of exons 18 through 21,
or utilizing either the PNAClamp™ EGFR Mutation Detection Kit (PANAGENE, Daejeon,
Korea) or the PANAMutyper™ R EGFR kit (PANAGENE, Daejeon, Korea), was performed in
all cases. For KRAS gene analysis, direct DNA sequencing of codons 12 and 13, or utilizing the
PANAMutyper™ R KRAS kit (PANAGENE, Daejeon, Korea) was performed in all cases.
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ALK and ROS1 rearrangement analysis
To identify ALK and ROS1 rearrangements, IHC was performed using the ALK (rabbit mono-
clonal, clone D5F3, Cell Signaling Technology, Danvers, MA, USA) and ROS1 (rabbit mono-
clonal, clone D4D6, Cell Signaling Technology, Danvers, MA, USA) antibodies. In IHC
positive cases, fluorescence in situ hybridization (FISH) was performed using a break-apart
ALK probe (Vysis LSI Dual Color, Break Apart Rearrangement Probe kit, Abbott Molecular,
Abbott Park, IL, USA) or ROS1 probe (Abbott Molecular). ALK or ROS1 rearrangements were
scored as positive when more than 15% of tumor cells displayed split signals or isolated signals
containing a kinase domain (red for ALK and green for ROS1).
Statistical analysis
The chi-square or Fisher’s exact test was used to evaluate the association between HER2 status
and clinicopathological parameters. Correlations between IHC and SISH were estimated using
Spearman’s correlation coefficients (kappa); kappa values>0.75 denote excellent agreement,
values between 0.4 and 0.75 denote fairly good agreement, and values<0.4 denote poor agree-
ment. Overall survival (OS) was assessed from the date of surgery to that of death or the last
follow-up visit. Disease-free survival (DFS) was measured from the date of surgery to that of
cancer recurrence or the last follow-up visit. Survival rates were calculated using the Kaplan—
Meier method, and the differences were analyzed using the log-rank test. Multivariate analysis
was performed using the Cox proportional hazards model, which was expressed by the hazard
ratio with a 95% confidence interval. P-values<0.05 were considered statistically significant.




According to criteria described above, 419 patients were ultimately selected for analysis: 321
had adenocarcinomas and 96 had squamous cell carcinomas. Characteristics of patients with
adenocarcinoma are summarized in Table 1. Lung adenocarcinoma samples were derived
from 163 men and 158 women aged 33–90 years (mean = 61.8 years). This population
included 196 non-smokers (61.6%) and 125 former or current smokers (38.9%).
HER2 overexpression and its clinicopathological significance
Of 321 adenocarcinomas, membranous or cytoplasmic HER2 expression was classified as neg-
ative in 192 cases (59.8%), low in 98 (30.5%), intermediate in 25 (7.8%), and high in 6 (1.9%)
by the H-scoring method (Fig 1). Membranous expression of HER2 was scored as 0 in 248
samples (77.3%), 1+ in 48 (15.0%), 2+ in 21 (6.5%), and 3+ in 4 (1.2%) according to the
ASCO/CAP guidelines of breast cancer. Cytoplasmic expression without membranous stain-
ing was observed in 26 adenocarcinomas (8.1%). Among them, only one case showed a high
H-score, but did not exhibit HER2 amplification.
Clinicopathological findings observed in lung adenocarcinomas with or without HER2
overexpression are summarized in Table 1. High expression of HER2 (H-score200) was
more frequently found in adenocarcinomas with a predominantly papillary histology
(P = 0.029). Among HER2-overexpressing adenocarcinomas, 1 (16.7%) and 2 (33.3%) had
EGFR and KRASmutations, respectively, while none had ALK or ROS1 rearrangements.
HER2 alterations in lung adenocarcinoma
PLOS ONE | DOI:10.1371/journal.pone.0171280 February 1, 2017 4 / 13
Table 1. Patient characteristics according to HER2 protein overexpression and gene amplification.
Characteristics, n (%) Total Protein overexpression a Gene amplification b
Positive Negative P value Positive Negative P value
321 (100) 6 (1.9) 315 (98.1) 46 (14.3) 275 (85.7)
Age (years) 0.424 1.000
<62 171 (53.3) 2 (33.3) 169 (53.7) 25 (54.3) 147 (53.5)
62 150 (46.7) 4 (66.7) 146 (46.3) 21 (45.7) 128 (46.5)
Gender 1.000 0.429
Male 163 (50.8) 3 (50.0) 160 (50.8) 26 (56.5) 137 (49.8)
Female 158 (49.2) 3 (50.0) 155 (49.2) 20 (43.5) 138 (50.2)
Smoking status 0.681 0.746
Never 196 (61.1) 3 (50.0) 193 (61.3) 27 (58.7) 169 (61.5)
Former/current 125 (38.9) 3 (50.0) 122 (38.7) 19 (41.3) 106 (38.5)
Tumor size (cm) 0.697 0.628
3 187 (58.3) 3 (50.0) 184 (58.4) 25 (54.3) 163 (59.3)
>3 134 (41.7) 3 (50.0) 131 (41.6) 21 (45.7) 112 (40.7)
Nodal metastasis 0.187 0.242
Positive 111 (34.6) 4 (66.7) 107 (34.0) 20 (43.5) 92 (33.5)
Negative 210 (65.4) 2 (33.3) 208 (66.0) 26 (56.5) 183 (66.5)
Pathologic stage 0.104 0.661
I 177 (55.1) 2 (33.3) 175 (55.6) 25 (54.3) 151 (54.9)
II 58 (18.1) 0 (0) 58 (18.4) 6 (13) 52 (18.9)
III 79 (24.6) 4 (66.7) 75 (23.8) 14 (30.4) 66 (24)
IV 7 (2.2) 0 (0) 7 (2.2) 1 (2.2) 6 (2.2)
Histologic subtype 0.718 0.082
Lepidic 24 (7.5) 0 (0) 24 (7.6) 2 (4.3) 22 (8)
Acinar 154 (48) 2 (33.3) 152 (48.3) 27 (58.7) 126 (45.8)
Papillary 41 (12.8) 3 (50.0) 38 (12.1) 7 (15.2) 34 (12.4)
Micropapillary 30 (9.3) 0 (0) 30 (9.5) 6 (13) 24 (8.7)
Solid 57 (17.8) 0 (0) 57 (18.1) 4 (8.7) 54 (19.6)
Mucinous 15 (4.7) 1 (16.7) 14 (4.4) 0 (0) 15 (5.5)
Papillary predominant type 0.029 0.633
Positive 41 (12.8) 3 (50.0) 38 (12.1) 7 (15.2) 34 (12.4)
Negative 280 (87.2) 3 (50.0) 277 (87.9) 39 (84.8) 241 (87.6)
Pleural invasion 0.218 0.035
Positive 127 (39.6) 4 (66.7) 123 (39.0) 25 (54.3) 103 (37.5)
Negative 194 (60.4) 2 (33.3) 192 (61.0) 21 (45.7) 172 (62.5)
EGFR mutation 0.215 0.635
Positive 157 (48.9) 1 (16.7) 156 (49.5) 24 (52.2) 132 (48)
Negative 164 (51.1) 5 (83.3) 159 (50.5) 22 (47.8) 143 (52)
KRAS mutation 0.112 0.595
Positive 32 (10) 2 (33.3) 30 (9.5) 3 (6.5) 29 (10.5)
Negative 289 (90) 4 (66.7) 285 (90.5) 43 (93.5) 246 (89.5)
ALK rearrangement 1.000 0.329
Positive 20 (6.2) 0 (0) 20 (6.3) 1 (2.2) 19 (6.9)
Negative 301 (93.8) 6 (100) 295 (93.7) 45 (97.8) 256 (93.1)
ROS1 rearrangement 1.000 0.607
Positive 8 (2.5) 0 (0) 8 (2.5) 0 (0) 8 (2.9)
(Continued )
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HER2 gene amplification and its clinicopathological significance
Of 321 adenocarcinomas, the results of SISH were negative in 271 (84.4%), equivocal in 4
(1.2%), and positive in 46 (14.3%) according to the criteria described above (Fig 1). Clinico-
pathological findings observed in lung adenocarcinomas with or without HER2 gene amplifi-
cation are summarized in Table 1. Adenocarcinomas with pleural invasion were significantly
Table 1. (Continued)
Characteristics, n (%) Total Protein overexpression a Gene amplification b
Positive Negative P value Positive Negative P value
Negative 313 (97.5) 6 (100) 307 (97.5) 46 (100) 267 (97.1)
a HER2 protein overexpression denotes H-score200.
b HER2 gene amplification denotes HER2/CEP17 ratio2.0 or average HER2 copy number6.0 signals/cell.
doi:10.1371/journal.pone.0171280.t001
Fig 1. Representative images of HER2 immunohistochemistry and HER2 silver in situ hybridization. Shown are negative/low (A),
intermediate (B), and high (C) HER2 expression levels according to the H-scoring system; and HER2 expression scores of 0/1+ (D), 2+ (E), and 3+
(F) according to the ASCO/CAP breast cancer guidelines. A case with predominantly cytoplasmic staining is shown in (G). Silver in situ
hybridization with no amplification (H; which is the same case as ‘A’) and high-level amplification (I; which is the same case as ‘C’).
doi:10.1371/journal.pone.0171280.g001
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correlated with HER2 amplification (P = 0.035). Among HER2-amplified adenocarcinomas, 24
(52.2%) and 3 (6.5%) had EGFR and KRASmutations, respectively, while 1 (2.2%) showed
ALK rearrangement. Five cases (1.6%) were found to have high-level amplification. While the
statistical power was low owing to the small number of cases with high-level amplification,
these cases tended to correlate with large tumor sizes (P = 0.078), pleural invasion (P = 0.065),
and lymphovascular invasion (P = 0.053).
HER2 mutations
HER2mutations were detected in 7 of 104 driver mutation-negative (i.e., EGFR/KRAS/ALK/
ROS1 negative) adenocarcinomas examined (6.7%), and included mostly insertion mutations
in exon 20. The mutation types and clinicopathological features were summarized in Table 2.
The patients were mostly women or never-smokers. The range of HER2/CEP17 ratios and the
HER2 copy numbers were from 1.4 to 2.4 and from 3.2 to 4.8, respectively. No high-level
amplification was found in HER2mutated tumors.
Survival analysis of HER2 overexpression and gene amplification in
adenocarcinoma
Patients with overexpression of HER2 showed significantly shorter OS and DFS rates com-
pared to patients without HER2 overexpression according to the H-scoring method
(P = 0.008 and 0.034, respectively; Fig 2). Patients with amplification of the HER2 gene
tended to have shorter (albeit non-significant) OS rates compared to those without amplifi-
cation (P = 0.233). Patients with ‘high-level’ amplification of the HER2 gene exhibited shorter
DFS rates (P = 0.003; Fig 2).
Univariate analysis revealed that male sex (P<0.001), older age (62 years; P = 0.017),
larger tumor size (3 cm; P<0.001), smoking (P<0.001), a solid predominant type tumor
(P = 0.002), pleural invasion (P = 0.003), lymphovascular invasion (P<0.001), lymph node
metastasis (P<0.001), advanced pTNM stage (P<0.001), and HER2 protein overexpression
(H-score200; P = 0.008) were significantly correlated with poor OS. Shorter DFS rates were
related to younger age (<62 years; P = 0.003), larger tumor size (3 cm; p<0.001), solid pre-
dominant type tumors (P = 0.011), micropapillary predominant type tumors (P = 0.007),
pleural invasion (P = 0.001), lymphovascular invasion (P<0.001), lymph node metastasis
(P<0.001), advanced pTNM stage (P<0.001), HER2 protein overexpression (H-score200;
P = 0.034), and HER2 high-level amplification (P = 0.003). Multivariate analysis for OS identi-
fied male sex, older age, large tumor size, solid predominant type, advanced pTNM stage,
and HER2 overexpression as independent prognostic factors (Table 3). Poor DFS was
Table 2. Summary of HER2 mutated cases.
Case
No.






1 p.A775_G776 insYVMA (c. 2324_2325 ins12) 64 Female Never Acinar IIIa 1.7 3.5
2 p.G776>VC (c.2326_2327 insTGT) 55 Female Never Acinar IIIa 2.2 4.5
3 p.A775_G776 insYVMA (c. 2324_2325 ins12) 80 Female Never Acinar Ia 2.2 4.4
4 p.P780_Y781insGSP (c.2339_2340 ins9) 79 Female Never Micropapillary Ib 1.7 3.5
5 p.A775_G776 insYVMA (c. 2324_2325 ins12) 81 Female Former Acinar IIIa 1.4 3.2
6 p.A775_G776 insYVMA (c. 2324_2325 ins12) 55 Female Never Papillary IIIa 2.2 4.4
7 p.G776S(c. 2326 G>A) & p. V777_G778 insE(c.
2332_2333 insAGG)
58 Male Never Acinar IIIa 2.4 4.8
doi:10.1371/journal.pone.0171280.t002
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independently associated with younger age, larger tumors, lymph node metastasis, and
advanced pTNM stage (Table 3).
Correlation of IHC with SISH
HER2 protein expression was significantly associated with gene amplification; however, IHC
and SISH showed poor concordance (Table 4). The sensitivities and specificities of IHC for
detecting amplification were as follows: 23.9% and 92.7% when the H-score cutoff was100,
and 23.9% and 94.9% when the cutoff was2+, respectively.
Fig 2. Overall and disease-free survival curves according to the HER2 immunohistochemistry H-score (A and B,
respectively) and according to high-level amplification by HER2 as detected by silver in situ hybridization (C and D,
respectively).
doi:10.1371/journal.pone.0171280.g002
HER2 alterations in lung adenocarcinoma
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Discussion
In the present study, we investigated HER2 protein expression and genetic alterations in
patients with lung adenocarcinomas and their associations with clinicopathological features
and prognosis. We observed that the frequency of HER2 overexpression and gene amplifica-
tion were 1.9% and 14.3% in adenocarcinomas, respectively, and that protein overexpression
and high amplification were associated with poor prognosis. In addition, HER2mutation was
identified in 6.7% of driver oncogene-negative adenocarcinomas.
Previous studies of HER2 overexpression in NSCLC have defined IHC positivity as only
membranous expression [10,25–28]. However, we additionally used the H-scoring method
that incorporates both cytoplasmic and membranous staining patterns. In adenocarcinomas,
Table 3. Multivariate survival analyses.
Overall survival
Variables P value HRa 95% CIb
Male 0.004 1.851 1.224–2.800
Age 62 0.004 1.832 1.215–2.761
Size 3cm 0.025 1.602 1.060–2.420
Solid predominant type 0.043 1.608 1.015–2.546
HER2 overexpressionc 0.009 3.999 1.404–11.394
pTNM stage <0.001 6.432 2.412–17.151
Disease-free survival
Variables P value HR 95% CI
Age < 62 0.001 1.796 1.270–2.538
Size 3cm <0.001 2.242 1.573–3.194
Lymph node metastasis 0.028 2.014 1.078–3.762
pTNM stage 0.021 3.521 1.214–10.218
a. HR, hazard ratio;
b. CI, confidence interval;
c. HER2 protein overexpression denotes H-score200
doi:10.1371/journal.pone.0171280.t003
Table 4. Correlation between HER2 immunohistochemistry and silver in situ hybridization.
Total, n (%) SISH P value kappa
Amplification No amplification
IHC (H score) <0.001 0.087
0 192 (59.8) 18 (39.1) 174 (63.3)
1~99 98 (30.5) 17 (37.0) 81 (29.5)
100~199 25 (7.8) 8 (17.4) 17 (6.2)
200~300 6 (1.9) 3 (6.5) 3 (1.1)
IHC (membranous)a <0.001 0.154
0 248 (77.3) 24 (52.2) 224 (81.5)
1+ 48 (15.0) 11 (23.9) 37 (13.5)
2+ 21 (6.5) 8 (17.4) 13 (4.7)
3+ 4 (1.2) 3 (6.5) 1 (0.4)
Total 321 46 275
a ASCO/CAP guidelines of breast cancer
doi:10.1371/journal.pone.0171280.t004
HER2 alterations in lung adenocarcinoma
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9.7% and 7.7% of tumors showed intermediate or stronger staining (by the H-scoring method)
and 2+ or greater expression (by the ASCO/CAP guidelines), respectively. Although the crite-
ria for positivity varied between studies, our positive staining rates are comparable to those
observed in previous studies (2.4–38%) [7,10,11]. The percentage of H-scores200 and
ASCO/CAP scores of 3+, indicating high expression, were 1.9% and 1.2%, respectively. In con-
trast to previous studies that showed a correlation between HER2 overexpression and both
lymph node metastasis and higher tumor stage [25,26], we found that 50% of HER2-overex-
pressed tumors were papillary predominant adenocarcinomas. Moreover, an H-score200
group significantly correlated with shorter OS and DFS rates, and was found to be an indepen-
dent prognostic factor. This result is consistent with previous meta-analyses that have deter-
mined HER2 overexpression to be a poor prognostic factor in adenocarcinomas [11,29].
HER2 amplification was detected by SISH in 14.3% of adenocarcinomas according to the
criteria used in breast cancer. A few previous studies using SISH showed similar rates (1.6–
20.4%) and revealed female sex, younger age, and papillary-predominant histology to be pre-
dictive clinicopathological parameters [10,25,26]. In our cohort, HER2-amplified adenocarci-
nomas more frequently presented with pleural invasion; this group of patients tended to have
shorter OS rates (although the difference was not significant). Several investigations that evalu-
ated HER2 amplification by FISH or SISH also have failed to show a significant relationship
between such amplification and prognosis [11,29] However, in our study, high-level amplifica-
tion (defined as a HER2/CEP17 ratio5.0 or an average HER2 copy number10.0 signals/
cell) correlated significantly with poor DFS.
In the present study, HER2 overexpression or gene amplification was not mutually exclu-
sive to other driver mutations. EGFR and KRASmutations were simultaneously found in
16.7% and 33.3% of HER2-overexpressing adenocarcinomas, respectively, as well as in 52.2%
and 6.5% of HER2-amplified adenocarcinomas, respectively. This suggests that HER2 deregu-
lation may be involved in cancer progression and acquired resistance [30]. To that end, recent
studies have reported that HER2 amplification is one of the mechanisms of acquired resistance
to EGFR TKIs [30,31]. However, of 104 driver mutation-negative cases, 11 (10.6%) harbored
HER2 protein overexpression, HER2 high-level amplification, or HER2 gene mutations. Tar-
geted therapies against HER2 activation can be considered as a therapeutic option in patients
with such HER2 alterations who have no driver mutations.
HER2 mutations were detected in 6.7% (7 of 104) of driver mutation-negative adenocarci-
nomas. Assuming that driver alterations are mutually exclusive, the frequency of HER2
mutations was 2.2% (7 of 321) in our cohort. Most reported HER2 mutations involve a
A775_G776insYVMA insertion/duplication in exon 20 [12,32] as was observed in 4 of our
cases. High-level gene amplification or protein overexpression was not found in HER2
mutated tumors.
Diagnostic criteria or specific algorithms for selecting patients for HER2 targeted therapy
has not yet been established in lung cancer. In the present study, HER2 IHC and SISH were
well correlated as shown in previous studies, but demonstrated poor concordance with each
other as well as poor sensitivity; this is contrary to findings observed in breast cancers. This
suggests that HER2 dysregulation might be more complex in lung cancers than in breast can-
cers, and that IHC may not be suitable as a screening tool for cases with gene amplification.
Therefore, specific HER2 alterations, such as protein overexpression, gene amplification, or
genetic mutations, should be investigated for their correlation with drug responsiveness in
clinical trials to determine the most robustly predictive biomarkers.
There are limitations for our study. This was a retrospective study, which means that inher-
ent biases may exist. Since the frequency of each alteration is low, further multi-institutional
studies are necessary to confirm the results.
HER2 alterations in lung adenocarcinoma
PLOS ONE | DOI:10.1371/journal.pone.0171280 February 1, 2017 10 / 13
Conclusion
We observed HER2 overexpression and gene amplification in 1.9% and 14.3% of adenocarci-
nomas, respectively. HER2mutations were identified in 6.7% of driver oncogene-negative ade-
nocarcinomas. HER2 overexpression was correlated with papillary predominant histology,
and was an independent poor prognostic factor for OS. Moreover, high-level HER2 amplifica-
tion was associated with poor DFS. Since targeted agents are currently being tested in clinical
trials, determining the HER2 status can influence the treatment of patients with molecularly
defined lung adenocarcinoma, as well as provide prognostic stratification.6.7
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